Strategic Business Shift: LyondellBasell Divests EO&D Business, Enhancing Focus On Core Operations

LyondellBasell Industries NV (NYSE: LYB) disclosed a deal to sell its Ethylene Oxide & Derivatives (EO&D) business and the Bayport, Texas production facility to 

LyondellBasell Industries NV (NYSE:LYB) disclosed a deal to sell its Ethylene Oxide & Derivatives (EO&D) business and the Bayport, Texas production facility to INEOS Oxide for $700 million. 

The transaction is expected to close in Q2 2024 following the completion of the planned maintenance at the facility, subject to regulatory and other customary closing conditions. 

Peter Vanacker, CEO, said, “Successful execution of this strategic pillar involves making difficult decisions to divest businesses which are not part of our core. We remain proud of the positive cash generation, access to advantaged feedstocks, reliability and highly skilled team that makes up the EO&D business and are excited to have reached an agreement with INEOS to enable the business to continue generating value under different ownership.”

Last month, LYB said it plans to build the company’s first industrial-scale catalytic advanced recycling demonstration plant at its Wesseling, Germany, site.

As of September 30, 2023, cash and liquid investments stood at $2.84 billion.

Price Action: LYB shares traded higher by 1.57% at $93.63 on the last check Friday.

Total
0
Shares
Related Posts
Read More

T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale In Company History; The Initial Order Includes Seven T2DX Instruments, Valued At More Than $450,000, With The Potential For Nine Additional Instruments To Be Sold And Deployed

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the second largest sale of sepsis-driven T2Dx® Instruments in

TTOO